The first human clinical trial, led by an international team of researchers and published in the New England Journal of Medicine, found that cetidegrasib, an investigational targeted therapy drug designed to eliminate a key cancer-driving protein called KRAS G12D, shows encouraging early activity in patients with advanced lung and pancreas cancer.
Please follow and like us:
